Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Top Cited Papers
Open Access
- 28 July 2016
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 375 (4), 323-334
- https://doi.org/10.1056/nejmoa1515920
Abstract
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. We wanted to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified component of the secondary microvascular outcome of that trial.Keywords
This publication has 39 references indexed in Scilit:
- Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global OutcomesKidney International, 2015
- Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2014
- The effect of RAAS blockade on the progression of diabetic nephropathyNature Reviews Nephrology, 2013
- Intensive glucose control improves kidney outcomes in patients with type 2 diabetesKidney International, 2013
- Kidney Disease and Increased Mortality Risk in Type 2 DiabetesJournal of the American Society of Nephrology, 2013
- Role of Intensive Glucose Control in Development of Renal End Points in Type 2 Diabetes MellitusArchives of Internal Medicine, 2012
- Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United StatesJAMA, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998